Search
Now showing items 271-280 of 591
Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients.
(FERRATA STORTI FOUNDATION, 2021-10-01)
Not available.
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-09-10)
PURPOSE: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood. Despite aggressive therapy, the 5-year survival rate for patients with metastatic or recurrent disease remains poor, and beyond PAX-FOXO1 fusion ...
Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients.
(OXFORD UNIV PRESS, 2021-01-01)
BACKGROUND: The use of liquid biopsy is of potential high importance for children with high grade (HGG) and diffuse midline gliomas (DMG), particularly where surgical procedures are limited, and invasive biopsy sampling ...
The clinical and molecular significance associated with STING signaling in breast cancer.
(NATURE RESEARCH, 2021-06-25)
STING signaling in cancer is a crucial component of response to immunotherapy and other anti-cancer treatments. Currently, there is no robust method of measuring STING activation in cancer. Here, we describe an ...
Systemic therapy for early breast cancer in older adults: current status and prospects.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-11-01)
PURPOSE OF REVIEW: In this review, we describe the evidence on the efficacy and the safety of systemic treatments for the management of early breast cancer (EBC) in older individuals. RECENT FINDINGS: Chemotherapy has a ...
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial.
(FERRATA STORTI FOUNDATION, 2021-07-01)
The optimal way to use immunomodulatory drugs as components of induction and maintenance therapy for multiple myeloma is unresolved. We addressed this question in a large phase III randomized trial, Myeloma XI. Patients ...
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
(OXFORD UNIV PRESS INC, 2021-01-04)
BACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ...
Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
(OXFORD UNIV PRESS INC, 2021-03-01)
BACKGROUND: There are no established molecular biomarkers for patients with breast cancer receiving combination endocrine and CDK4/6 inhibitor (CDK4/6i). We aimed to determine whether genomic markers in circulating tumor ...
Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy.
(ELSEVIER SCIENCE LONDON, 2021-01-01)
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.
(NATURE PORTFOLIO, 2021-02-17)
Breast cancer (BC) risk for BRCA1 and BRCA2 mutation carriers varies by genetic and familial factors. About 50 common variants have been shown to modify BC risk for mutation carriers. All but three, were identified in ...